摘要
目的:观察曲美他嗪辅佐治疗冠心病合并慢性心力衰竭的临床疗效。方法:选择61例冠心病合并慢性心力衰竭的患者,随机分为曲美他嗪治疗组(30例)和对照组(31例)。曲美他嗪组在常规心衰治疗基础上加用曲美他嗪(20 mg,tid)。两组均连续治疗6个月。分析治疗前后心功能级别、左室射血分数(LVEF)及N-末端脑钠素前体(NT-ProBNP)的变化。结果:6个月后曲美他嗪组与对照组相比,心功能级别分别降低36.4%、30.2%(P<0.01),LVEF分别提高22.5%、13.0%(P<0.05),两组NT-ProBNP水平均较治疗前明显改善(P<0.05),分别降低49.6%、29.0%(P<0.05)。结论:在常规心衰治疗基础上加用曲美他嗪能明显提高疗效。
Objective： To explore the therapeutic effects of trimetazidine（TMZ） in patients with coronary artery disease（ACD） and congestive heart failure（CHF）.Methods： A total of 61 CAD patients with CHF were randomly divided into two groups： conventional therapy group and TMZ group（TMZ＋conventional therapy）,and treated for 6 months.All patients underwent two-dimensional echocardiography,the levels of plasma N-terminal pro-B-type natriuretic peptide（NT-proBNP） were determined and the changes of left ventricular ejection fraction（LVEF） and New York Heart Association（NYHA） functional class were evaluated.Results： Treated for 6 months,NYHA functional classes and NT-proBNP levels were significantly decreased,LVEF was significantly increased from baseline in both groups.These changes were more significant in TZM group vs conventional group： the reduction of NYHA functional class was 37.5% vs 30.7%（P0.01）,the increase of plasma NT-proBNP was 49.6% vs 29.0%（P0.05） and the increase of LVEF was increased 23.7% vs 13.0%（P0.05）.Conclusion： Based on the conventional therapy of heart failure,application of TMZ can prominently improve the cardiac function.
出处
《药学与临床研究》
2011年第5期454-456,共3页
Pharmaceutical and Clinical Research
关键词
冠心病
充血性心力衰竭
N-末端脑钠素前体
曲美他嗪
Coronary artery disease
Congestive heart failure
N-terminal pro-B-type natriuretic peptide
Trimetazidine
